These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 33910619)

  • 21. Colchicine use and the risk of CKD progression: a multicentre nested case-control study.
    Kim HW; Joo YS; Yun HR; Kim JY; Jhee JH; Roh YH; Park JT; Chang TI; Yoo TH; Kang SW; Han SH
    Rheumatology (Oxford); 2022 Nov; 61(11):4314-4323. PubMed ID: 35139160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Gout management: an update].
    Ankli B; Krähenbühl S
    Ther Umsch; 2016; 73(3):115-24. PubMed ID: 27008442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics considerations for gout treatments.
    Richette P; Frazier A; Bardin T
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):949-57. PubMed ID: 24809930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How flare prevention outcomes are reported in gout studies: A systematic review and content analysis of randomized controlled trials.
    Stewart S; Tallon A; Taylor WJ; Gaffo A; Dalbeth N
    Semin Arthritis Rheum; 2020 Apr; 50(2):303-313. PubMed ID: 31796212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
    Saag KG; Becker MA; Whelton A; Hunt B; Castillo M; Kisfalvi K; Gunawardhana L
    Arthritis Rheumatol; 2019 Jan; 71(1):143-153. PubMed ID: 30073793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis.
    Zeng L; Qasim A; Neogi T; Fitzgerald JD; Dalbeth N; Mikuls TR; Guyatt GH; Brignardello-Petersen R
    Arthritis Care Res (Hoboken); 2021 May; 73(5):755-764. PubMed ID: 32741131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapeutic management of gout in patients with cardiac disease.
    Chan CW; Yap YN
    Expert Opin Pharmacother; 2018 Dec; 19(18):2011-2018. PubMed ID: 30345832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Patients with Gout and Kidney Disease: A Review of Available Therapies and Common Missteps.
    Kannuthurai V; Gaffo A
    Kidney360; 2023 Sep; 4(9):e1332-e1340. PubMed ID: 37526648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and treatment of gout among patients with chronic kidney disease in the Irish health system: A national study.
    Mohammed E; Browne LD; Kumar A U A; Adeeb F; Fraser AD; Stack AG
    PLoS One; 2019; 14(1):e0210487. PubMed ID: 30682034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3.
    Novella-Navarro M; Cabrera-Alarcon JL; Diaz-Torne C; Aramburu-Muñoz F; Janta I; Ortega de la O MC; Prada-Ojeda A; Sala-Icardo L; Urruticoechea-Arana A; García de la Peña Lefebvre P; Calvo-Aranda E
    Rheumatol Int; 2020 Jul; 40(7):1081-1087. PubMed ID: 31982955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing your patient with gout: a review of treatment options.
    Doghramji PP
    Postgrad Med; 2011 May; 123(3):56-71. PubMed ID: 21566416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Major unanswered questions in the clinical gout field.
    Stamp LK
    Curr Opin Rheumatol; 2017 Mar; 29(2):171-177. PubMed ID: 27926541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing Gout Flares in the Elderly: Practical Considerations.
    Abhishek A
    Drugs Aging; 2017 Dec; 34(12):873-880. PubMed ID: 29214511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
    Keenan RT
    Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of interleukin-1 inhibitors in the management of gout.
    Tran TH; Pham JT; Shafeeq H; Manigault KR; Arya V
    Pharmacotherapy; 2013 Jul; 33(7):744-53. PubMed ID: 23553601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial.
    Sircar D; Chatterjee S; Waikhom R; Golay V; Raychaudhury A; Chatterjee S; Pandey R
    Am J Kidney Dis; 2015 Dec; 66(6):945-50. PubMed ID: 26233732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in the pharmacotherapy of gout.
    Sundy JS
    Curr Opin Rheumatol; 2010 Mar; 22(2):188-93. PubMed ID: 20110792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.
    Gunawardhana L; Becker MA; Whelton A; Hunt B; Castillo M; Saag K
    Arthritis Res Ther; 2018 May; 20(1):99. PubMed ID: 29848361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of gout in the older adult.
    Fravel MA; Ernst ME
    Am J Geriatr Pharmacother; 2011 Oct; 9(5):271-85. PubMed ID: 21849262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.